Lupin Limited — Updates, 12-02-2025: Press Release (Revised)

Lupin Limited reported strong financial performance for the quarter ending December 31, 2024, with notable increases in sales and profitability. Sales reached INR 56,186 Mn, a 10.6% year-on-year growth, while EBITDA surged 32.1% to INR 14,096 Mn, resulting in an EBITDA margin of 25.1%. PBT increased by 45.5% YoY to INR 10,713 Mn, and PAT rose 38.8% YoY to INR 8,589 Mn.

In terms of regional performance, North America sales climbed 12.3% to INR 21,213 Mn, driven by strong growth in new product launches. India saw an 11.9% increase in sales to INR 19,305 Mn. EMEA sales grew 20.9%, while Emerging Markets recorded a slight decline. The company maintained its leadership position in the U.S. generics market.

Lupin's investment in R&D for the quarter was INR 4,344 Mn, reflecting its commitment to innovation. The outlook remains positive with sustained growth expected from key regions and new product developments, making it a stock to watch closely for potential growth opportunities.